Roche third quarter sales beat forecasts as Ocrevus shines

  • Roche's third-quarter sales rose 6 percent to 13.1 billion Swiss francs ($13.37 billion)
  • This was helped by better-than-expected revenue from its new multiple sclerosis medicine Ocrevus
The headquarters of Roche AG in Basel, Switzerland.
Gianluca Colla | Bloomberg | Getty Images
The headquarters of Roche AG in Basel, Switzerland.

Roche's third-quarter sales rose 6 percent, beating analyst forecasts as the company was helped by better-than-expected revenue from its new multiple sclerosis medicine Ocrevus,
the Swiss drugmaker said on Thursday.

Roche third-quarter sales were 13.1 billion Swiss francs ($13.37 billion), compared to the 13.04 billion francs average estimate by analysts in a Reuters poll. Sales of Ocrevus were 308 million francs, better than the poll average of 228 million and accelerating from 192 million francs in the second quarter.